Abstract: A radio-frequency (RF) front-end circuit includes a tunable filter, a negative transconductance circuit coupled with the tunable filter to produce a tuning oscillation signal, and a counter arranged to determine a frequency of the tuning oscillation signal. The RF front-end circuit also includes a control circuit arranged to shift the frequency of the tuning oscillation signal by adjusting the tunable filter until the frequency of the tuning oscillation signal falls within an acceptable frequency range corresponding to a desired channel frequency band.

Abstract: A group of amino substituted benzoyl derivatives, their preparation and their use. The screening and research on an antiviral drug with hA3G/Vif as a target point proves that the 3-amino benzoyl derivatives not only have the combined activity for the hA3G/Vif, but also have a function of inhibiting replication of viruses. The present invention provides the possible breakthrough progress for the problem of HIV drug resistance, thereby providing a novel clinical antiviral drug which has higher efficiency.

Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.

Abstract: A lifter assembly for actuating a needle of an automatic medication delivery device, includes a motor, a speed reduction device driven by the motor, an output shaft driven by the speed reduction device via a rigid transmission device, a driving lever configured to move the needle, the driving lever being connected to and driven by the output shaft, and a sensing device configured to sense the rotation position of the output shaft. The speed reduction device comprises a worm in mesh with a worm gear. The output shaft, the worm gear and the rigid transmission device cooperatively constitute a four-bar linkage mechanism.

Abstract: A multiple-input multiple-output (MIMO) device includes a substrate, a shielding cover and a MIMO antenna. The shielding cover is positioned on the substrate, and includes a plurality of sidewalls. The MIMO antenna includes a first solid antenna, a second solid antenna, and a plane antenna. The first solid antenna and the second solid antenna are electrically connected to two ends of one sidewall of the shielding cover, respectively. The first plane antenna is configured on the substrate, and disposed between the first solid antenna and the second solid antenna.

Abstract: A system and method for simulating resource allocation, where the allocation strategies which can be simulated include those of prior art but also include a large class of important allocation strategies that are not possible or not easy to simulate using prior art techniques and systems is described. A location limiting allocation strategy is also described. This strategy supports resource capacity schedules and request priorities as supported by prior art, but simultaneously supports the enforcement of allocation limits applied to a property expressed in the allocation request, namely the location of the work to be performed, or a location, resource pair to perform the work.

Abstract: Methods and compositions containing a berberine compound or berberine related or proto-berberine or derivative compound are provided for the prevention and treatment of metabolic and cardiovascular disorders including metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of metabolic syndrome, hyperlipidemia, obesity, diabetes, insulin resistance, hyperglycemia, hypertension and elevated cholesterol.

Abstract: A wireless device including a controller controlling operations of the wireless device based on the operating mode of the wireless device for data services. The operating mode is one of a normal mode and a serving mode. The normal mode being where the wireless device acts as a normal endpoint of a data communication system and the serving mode being where the wireless device serves as a service access point for the data communication system.

Abstract: It is presently accepted that the mechanism of action for all anti-tumor tubulin ligands involves the perturbation of microtubule dynamics during the G2/M phase of cell division and subsequent entry into apoptosis (1). In this invention, we report a novel tubulin ligands which have a unique mechanism of action. These compounds, halogenated derivatives of acetamido benzoyl ethyl ester (HAABE), arrest cancer cells in S-phase and cause cell death by a combination of apoptosis (DNA ladder) and necrosis (DNA degradation) type mechanisms. Normal cells are not affected at the same concentrations of compound. The ligands bind covalently to tubulin in vitro and in vivo and shows potent cancericidal activity in tissue culture assays and in animal tumor models. These compounds target early S-phase at the G1/S transition rather than the G2/M phase and mitotic arrest.

Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.

Abstract: The present invention provides for haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurea, 3-bromoacetoamido, benzoylurea, 3-iodoacetoamido, benzoylurea, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with methods of making and using the derivatives, are also provided.

Abstract: Novel &agr;-pyrones are described. The &agr;-pyrones are useful in a method for controlling &agr;-pyrone responsive states in a mammal. The method includes administering to a mammal a therapeutically effective amount of an &agr;-pyrone such that control of &agr;-pyrone responsive states in a mammal occurs. &agr;-Pyrone responsive states can be associated with undesirable cell proliferation such as bacteria or cancer. Packaged pharmaceuticals and pharmaceutical compositions including the novel &agr;-pyrones are also described.

Abstract: It is presently accepted that the mechanism of action for all anti-tumor tubulin ligands involves the perturbation of microtubule dynamics during the G2/M phase of cell division and subsequent entry into apoptosis (1). In this invention, we report a novel tubulin ligands which have a unique mechanism of action. These compounds,. halogenated derivatives of acetamido benzoyl ethyl ester (HAABE), arrest cancer cells in S-phase and cause cell death by a combination of apoptosis (DNA ladder) and necrosis (DNA degradation) type mechanisms. Normal cells are not affected at the same concentrations of compound. The ligands bind covalently to tubulin in vitro and in vivo and shows potent cancericidal activity in tissue culture assays and in animal tumor models. These compounds target early S-phase at the G1/S transition rather than the G2/M phase and mitotic arrest.

Abstract: A method of treating cancer with a pharmaceutical composition containing a pine root (Deutero Mycetes) fungal metabolite or an analog or derivative thereof.

Abstract: Haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurea, 3-bromoacetoamido, benzoylurea, 3-iodoacetoamido, benzoylurea, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with method of making and using the derivatives, are also provided.

Abstract: Novel &agr;-pyrones are described. The &agr;-pyrones are useful in a method for controlling &agr;-pyrone responsive states in a mammal. The method includes administering to a mammal a therapeutically effective amount of an &agr;-pyrone such that control of &agr;-pyrone responsive states in a mammal occurs. &agr;-Pyrone responsive states can be associated with undesirable cell proliferation such as bacteria or cancer. Packaged pharmaceuticals and pharmaceutical compositions including the novel &agr;-pyrones are also described.

Abstract: Haloacetoamido, benzoic acid derivatives having anti-tumorigenic activity are inclosed. Examples of the haloacetoamido, benzoic acid derivatives include 3-chloroacetoamido, benzoylurca, 3-bromoacctoamido, benzoylurea, 3-todoacetoamido, benzoylurca, ethyl-3-chloroacetoamido, benzoate, ethyl-3-bromoacetoamido, benzoate and ethyl-3-iodoacetoamido, benzoate. Intermediates for synthesizing the derivatives, along with method of making and using the derivatives, are also provided.

Abstract: A pine root (Deutero mycetes) fungal metabolite and analogs thereof having antifungal activity.

Abstract: Novel .alpha.-pyrones are described. The .alpha.-pyrones are useful in a method for controlling .alpha.-pyrone responsive states in a mammal. The method includes administering to a mammal a therapeutically effective amount of an .alpha.-pyrone such that control of .alpha.-pyrone responsive states in a mammal occurs. .alpha.-Pyrone responsive states can be associated with undesirable cell proliferation such as bacteria or cancer. Packaged pharmaceuticals and pharmaceutical compositions including the novel .alpha.-pyrones are also described.

Abstract: A method of treating cancer with a pharmaceutical composition containing a pine root (Deutero Mycetes) fungal metabolite or an analog or derivative thereof.